KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Account Payables (2020 - 2024)

AbCellera Biologics (ABCL) has disclosed Change in Account Payables for 5 consecutive years, with $4.0 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Change in Account Payables rose 129.93% year-over-year to $4.0 million, compared with a TTM value of -$9.4 million through Sep 2024, up 48.48%, and an annual FY2022 reading of -$3.2 million, down 325.71% over the prior year.
  • Change in Account Payables was $4.0 million for Q3 2024 at AbCellera Biologics, down from $4.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $27.3 million in Q2 2022 and bottomed at -$29.2 million in Q3 2022.
  • Average Change in Account Payables over 5 years is $730444.4, with a median of $1.5 million recorded in 2020.
  • The sharpest move saw Change in Account Payables tumbled 3229.49% in 2021, then surged 1656.63% in 2022.
  • Year by year, Change in Account Payables stood at $24.3 million in 2020, then crashed by 92.94% to $1.7 million in 2021, then plummeted by 217.28% to -$2.0 million in 2022, then tumbled by 568.29% to -$13.4 million in 2023, then skyrocketed by 129.93% to $4.0 million in 2024.
  • Business Quant data shows Change in Account Payables for ABCL at $4.0 million in Q3 2024, $4.9 million in Q2 2024, and -$4.9 million in Q1 2024.